Voltaren Arthritis Pain Gel: OTC relief for joint pain in focus

Responsible: ad hoc news B2B & Pro Desk. Reviewed prior to publication on June 13, 2026 at 10:32:32 ET. Details in the imprint.

Voltaren Arthritis Pain Gel is one of the best-known topical nonsteroidal anti-inflammatory drugs (NSAIDs) now sold over the counter in the United States, offering on-skin relief for adults with arthritis pain in joints like hands, wrists, elbows, knees, ankles, and feet. The gel contains 1 percent diclofenac sodium, the same active ingredient that was previously prescription-only in the US, and is marketed for up to 21 days of self-directed use for arthritis pain in a single joint unless a doctor advises otherwise. Distributed by Haleon in many markets following its spin off from GSK, Voltaren remains closely associated with GSK's consumer-health heritage and continues to be part of a broad joint venture and brand-rights history that helped build its presence in pharmacies worldwide.

What Voltaren Arthritis Pain Gel is designed to do

Voltaren Arthritis Pain Gel is designed specifically to treat arthritis pain in joints close to the skin surface, such as knees and hands, rather than deep back or hip pain. According to the official US drug facts label, each gram of gel delivers 10 mg of diclofenac sodium, classified as a topical NSAID that relieves pain by reducing inflammation within the affected joint tissues. The formulation is indicated for adults 18 years and older for the temporary relief of arthritis pain and is not approved for use in children under that age threshold.

The product directions emphasize regular application rather than as-needed spot use: the typical regimen is 4 times per day on the affected joint, with a maximum of 32 g per day across all treated joints. The label instructs users not to use more than directed, not to apply to more than 2 body areas at the same time without medical advice, and to avoid occlusive dressings or heating pads on the treated area. Because the medicine works locally but can still be absorbed, the drug facts warn that it may cause systemic side effects similar to oral NSAIDs, including stomach bleeding or cardiovascular risks, especially if someone exceeds the recommended dose or combines it with other NSAID medications.

In the US, Voltaren Arthritis Pain Gel is available as an over-the-counter product at major retailers such as CVS, Walgreens, Walmart, Target, and online marketplaces, with common pack sizes of around 3.5 oz (100 g) and 5.3 oz (150 g). Public retail listings typically show everyday prices in the range of roughly $10 to $25 per tube, depending on size and retailer promotions, which places Voltaren among the higher-priced but still mainstream topical pain-relief options in US drugstores. For adult consumers comparing options on the shelf, the key distinction is that Voltaren provides an NSAID mechanism similar to ibuprofen or naproxen tablets but targets the application to the skin over the painful joint instead of delivering the drug throughout the entire body.

Clinical and regulatory materials describe Voltaren's active ingredient, diclofenac sodium, as having been studied extensively in osteoarthritis of the knee and hand, where topical application can help reduce pain and improve function in some patients compared with placebo. While individual results vary, topical diclofenac has been part of treatment guidelines in several countries for localized osteoarthritis, especially for patients seeking alternatives or adjuncts to oral NSAIDs. Because Voltaren is now available without a prescription in the United States, pharmacists often play a frontline role in counseling customers on correct dosing, maximum duration of self-treatment, and when to refer someone to a physician, such as when joint pain remains for more than 21 days, worsens, or is accompanied by concerning symptoms.

Safety warnings on the US label include standard NSAID boxed warnings regarding potential increased risk of heart attack and stroke with systemic exposure, particularly when used at higher doses or over longer durations than recommended. The product is also contraindicated for individuals with known allergies to diclofenac or other NSAIDs, and the label instructs consumers to avoid use right before or after heart surgery such as coronary artery bypass graft (CABG). Additional precautions advise pregnant women in their third trimester not to use the gel due to potential risks to the unborn baby, and recommend that anyone taking blood thinners or other NSAIDs consult a doctor or pharmacist before use. The presence of these systemic-style warnings, even for a topical product, reflects regulators' assessment that sufficient diclofenac can be absorbed to trigger adverse events in vulnerable patients if the product is misused.

From a formulation standpoint, Voltaren Arthritis Pain Gel uses a non-greasy base designed to be rubbed into the skin until fully absorbed, leaving minimal residue. The included dosing card that comes in US retail packs is intended to help users measure the correct amount of gel in grams per dose based on a printed scale so that recommended daily gram limits are not exceeded. This dosing card is a distinct element compared with many cosmetic creams or simpler pain rubs that are applied in subjective amounts without clear quantitative guidance, and it reflects the product's heritage as a prescription-strength medicine brought into the OTC channel.

For Haleon, which holds and markets the Voltaren brand in many markets following its separation from GSK's core pharmaceuticals and vaccines business, Voltaren remains one of the headline brands in its pain-relief portfolio alongside products such as Advil and Panadol. Analysts and company materials describe pain relief as a key segment in global consumer health, and Voltaren's topical arthritis positioning allows Haleon and its historical partners to target aging populations, active adults, and patients who have been advised to limit systemic NSAIDs. While specific sales figures for Voltaren Arthritis Pain Gel in the United States are not always broken out, Haleon's disclosures have pointed to strong performance of the Voltaren franchise in recent years as consumers increasingly seek localized, non-opioid pain management solutions.

For GSK, Voltaren is part of a legacy consumer-health portfolio that has transitioned into Haleon, allowing GSK to focus more on prescription medicines and vaccines through its listed entity while still benefiting indirectly from its former consumer brands' visibility. Shares of GSK PLC (GB0009252882, ticker GSK) traded at $41.37 on NYSE on June 12, 2026.

This article was created with a.i. assistance and editorially reviewed. Product information is provided without warranty; prices and availability may change at any time. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.